Transfer of Naltrexone and its Metabolite 6,Β-Naltrexol into Human Milk

Abstract

The excretion of naltrexone and its primary metabolite 6,Β-naltrexol in breast milk from a 30-year-old lactating opiate addict undergoing oral naltrexone pharmacotherapy (5 mg/d) was studied. Concentrations of naltrexone and 6,Β-naltrexol in serial milk and plasma samples taken over a 19.3-hour period of a dose interval at steady state were measured by gas chromatography. The calculated infant dose relative to the maternal weight was 0.03% for naltrexone and 0.83% (as naltrexone equivalents) for 6,Β-naltrexol. Total relative infant dose estimated for the complete 24-hour dose intervalwas 1.06%. Her 6-week-old breastfed infant was healthy, achieving expected milestones, and showed no adverse effects. Only 6,Β-naltrexol was detected in infant plasma and at a very low concentration of 1.1 µ g/L. Use of naltrexone during breastfeeding should be undertaken only after an individual riskbenefit analysis. J Hum Lact. 20(3):322-326.

Keywords

naltrexone human milk infant dose

Get full access to this article

View all access options for this article.

References

1. United Nations Office for Drug Control and Crime Prevention .World Drug Report. Oxford,England: Oxford University Press; 2000:1-181.

2. Australian Institute of Health and Welfare . Statistics on Drug Use in Australia 2002. Canberra, Australia: Australian Institute of Health and Welfare; 2003:1-95.

3. O’Neil G , Hulse G , Armstrong J , et al.Rapid opioid detoxification in Australia. Acad Emerg Med. 2002;9:960.

4. Hulse G , O’Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol. 2002;42:569-573.

5. Hulse GK , O’Neil G , Pereira C , et al.Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust N Z J Obstet Gynaecol. 2001;41:424-428.

6. Hulse GK , O’Neil G. A possible role for implantable naltrexone in the managementof the high-risk pregnant heroin user. Aust N Z J Obstet Gynaecol. 2002;42:93-94.

7. Anonymous . Revia: MIMS Abbreviated Prescribing Information. EMIMS version 4.00.0604.St Leonards, Australia: Multi Media Australia Pty Limited; 2003.

8. Takemori AE , Portoghese PS. Selective naltrexone-derived opioid receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;32:239-269.

9. Wall ME , Perez-Reyes M , Brine DR , et al.Naltrexone disposition in man after subcutaneous administration. Drug Metab Dispos. 1984;12:677-682.

10.

10. Chan CF , Chiswell GM , Bencini R , et al.Quantification of naltrexone and 6,beta-naltrexol in plasma and milk using gas chromatographymass spectrometry: application to studies in the lactating sheep. J Chromatogr B Biomed Sci Appl. 2001;761:85-92.

11.

11. Thomann P. Non-compartmental analysis methods manual. In: Heinzel G , Woloszcak R , Thomann P , eds. Top Fit 2.0 Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Stuttgart, Germany: Gustav Fischer; 1993:5-66.

12.

12. Begg EJ , Duffull SB , Hackett LP , et al.Studying drugs in human milk: time to unify the approach. J Hum Lact. 2002;18:323-332.

13.

13. Bennett PN. Use of the monographs on drugs. In: Bennett PN , ed. Drugs and Human Lactation. Amsterdam, the Netherlands: Elsevier; 1996:67-74.

14.

14. Lucas A , Gibbs JA , Lyster RL , et al.Creamatocrit: simple clinical technique for estimating fat concentration and energy value of human milk. Br Med J (Clin Res Ed). 1978;1:1018-1020.

15.

15. Foster J , Brewer C , Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol. 2003;8:211-217.

16.

16. Ferrari A , Bertolotti M , Dell’Utri A , et al.Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts. Drug Alcohol Depend. 1998;52:211-220.